Supplementary Figure 9 from Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Year: 2024
Type: supplementary-materials
Abstract: Genomic characterization of NSCLC cases harboring oncogenic / likely oncogenic MET TKD mutations in cohort #2. (A) Oncoprint summarizing the genomic profile and (B) the TMB value of the 78 NSCLC cases with oncogenic / likely oncogenic MET TKD mutations without other concurrent driver alterations according to NCCN guidelines. (C) Comparison of the genomic profile of NSCLC cases with oncogenic / likely oncogenic MET TKD mutations (N=78) and METex14-altered NSCLC (N=2036)
Authors: Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K. Lee, Joao V. Alessi, Adriana Barrichello, Victor R. Vaz, Giuseppe Lamberti, Alessandro Di Federico, Malini M. Gandhi, Dimitris Gazgalis, William W. Feng, Jie Jiang, Simon Baldacci, Marie-Anaïs Locquet, Felix H. Gottlieb, Monica F. Chen, Elinton Lee, Danielle Haradon, Anna Smokovich, Emma Voligny, Tom Nguyen, Vikas K. Goel, Zachary Zimmerman, Sumandeep Atwal, Xinan Wang, Magda Bahcall, Rebecca S. Heist, Sumaiya Iqbal, Nishant Gandhi, Andrew Elliott, Ari M. Vanderwalde, Patrick C. Ma, Balazs Halmos, Stephen V. Liu, Jianwei Che, Alexa B. Schrock, Alexander Drilon, Pasi A. Jänne, Mark M. Awad
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4401274266